Lecanemab Injection Approved for Marketing by China NMPA

Recently, Lecanemab injection (Chinese trade name: Leqembi) of Eisai Inc. has been approved with the priority review and approval procedure by NMPA China for the treatment of patients with mild cognitive impairment or mild dementia stage of Alzheimer’s disease.

Extracellular deposits of Aβ, referred to as amyloid plaques, are one of the pathologic hallmarks of AD. Lecanemab is a recombinant human immunoglobulin gamma 1 (IgG1) monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid beta to reduce the amyloid beta plaque. The marketing of this variety provides new treatment options for Alzheimer’s disease treatment.